Trial Profile
Prospective, single center study on radium‑223 dichloride in patients with castration‑resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 02 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2018 New trial record
- 23 Jan 2018 Status changed from active, no longer recruiting to completed.